Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic study

Abstract Multiple myeloma (MM) is a blood cancer that, unfortunately, has a high morbidity and mortality rate. The VMP regimen, which includes bortezomib (BOR), melphalan (MEL), and prednisolone (PRD), is a safe and effective salvage regimen for refractory or relapsed MM. Up to now, there is no esta...

Full description

Saved in:
Bibliographic Details
Main Authors: Marco M. Z. Sharkawi, Noha H. Amin, Norhan R. Mohamed, Shimaa S. Zaki, Loah R. Hemeda
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-15078-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849344584218312704
author Marco M. Z. Sharkawi
Noha H. Amin
Norhan R. Mohamed
Shimaa S. Zaki
Loah R. Hemeda
author_facet Marco M. Z. Sharkawi
Noha H. Amin
Norhan R. Mohamed
Shimaa S. Zaki
Loah R. Hemeda
author_sort Marco M. Z. Sharkawi
collection DOAJ
description Abstract Multiple myeloma (MM) is a blood cancer that, unfortunately, has a high morbidity and mortality rate. The VMP regimen, which includes bortezomib (BOR), melphalan (MEL), and prednisolone (PRD), is a safe and effective salvage regimen for refractory or relapsed MM. Up to now, there is no established analytical method to determine the VMP regimen, nor has any study investigated the kinetic interactions among its components, thereby highlighting the need for further clinical investigation. In light of this, an environmentally friendly, fast, sensitive, and precise LC-MS/MS method was established to determine bortezomib, melphalan, prednisolone, and sildenafil (an internal standard) simultaneously as part of the in vivo pharmacokinetics research carried out on rats. The established LC-MS/MS method was applied using a mobile phase composed of a mixture of methanol: 0.1% aqueous solution of formic acid and a ZORBAX Eclipse Plus C18 column (4.6 mm × 150 mm, 5 μm) as a stationary phase. The cited drugs were ionized through positive ionization and detected using multi-reaction monitoring (MRM) mode with the following precursor→product transitions: m/z 367.3→226.3 for BOR, m/z 305.0→168.2 for MEL, m/z 545.0→147.5 for PRD, and m/z 475.3→283.4 for SIL. Following FDA guidelines, the developed method was validated and showed acceptable ranges. Subsequently, it was employed in an in vivo investigation using rats, where the quantitative assessment of each drug was performed following both single and combined treatment. This allowed for the investigation of potential drug-drug interactions and the calculation of all pharmacokinetic parameters to monitor the therapeutic effects of those medications. To ensure the safety and environmental friendliness of the developed method, four assessment tools were applied: the assessment of green profile (AGP), blue applicability grade index (BAGI), analytical greenness metric for sample preparation (AGREEprep), and green analytical procedure index (GAPI).
format Article
id doaj-art-7382f58f957a42b19baffcdbf8c29e12
institution Kabale University
issn 2045-2322
language English
publishDate 2025-08-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-7382f58f957a42b19baffcdbf8c29e122025-08-20T03:42:38ZengNature PortfolioScientific Reports2045-23222025-08-0115111310.1038/s41598-025-15078-6Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic studyMarco M. Z. Sharkawi0Noha H. Amin1Norhan R. Mohamed2Shimaa S. Zaki3Loah R. Hemeda4Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy , Beni-Suef University Alshaheed Shehata Ahmed Hegazy St. Department of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef UniversityDepartment of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef UniversityDepartment of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef UniversityDepartment of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef UniversityAbstract Multiple myeloma (MM) is a blood cancer that, unfortunately, has a high morbidity and mortality rate. The VMP regimen, which includes bortezomib (BOR), melphalan (MEL), and prednisolone (PRD), is a safe and effective salvage regimen for refractory or relapsed MM. Up to now, there is no established analytical method to determine the VMP regimen, nor has any study investigated the kinetic interactions among its components, thereby highlighting the need for further clinical investigation. In light of this, an environmentally friendly, fast, sensitive, and precise LC-MS/MS method was established to determine bortezomib, melphalan, prednisolone, and sildenafil (an internal standard) simultaneously as part of the in vivo pharmacokinetics research carried out on rats. The established LC-MS/MS method was applied using a mobile phase composed of a mixture of methanol: 0.1% aqueous solution of formic acid and a ZORBAX Eclipse Plus C18 column (4.6 mm × 150 mm, 5 μm) as a stationary phase. The cited drugs were ionized through positive ionization and detected using multi-reaction monitoring (MRM) mode with the following precursor→product transitions: m/z 367.3→226.3 for BOR, m/z 305.0→168.2 for MEL, m/z 545.0→147.5 for PRD, and m/z 475.3→283.4 for SIL. Following FDA guidelines, the developed method was validated and showed acceptable ranges. Subsequently, it was employed in an in vivo investigation using rats, where the quantitative assessment of each drug was performed following both single and combined treatment. This allowed for the investigation of potential drug-drug interactions and the calculation of all pharmacokinetic parameters to monitor the therapeutic effects of those medications. To ensure the safety and environmental friendliness of the developed method, four assessment tools were applied: the assessment of green profile (AGP), blue applicability grade index (BAGI), analytical greenness metric for sample preparation (AGREEprep), and green analytical procedure index (GAPI).https://doi.org/10.1038/s41598-025-15078-6BortezomibMelphalanPrednisoloneLC-MS/MS methodGreen chemistryPharmacokinetics
spellingShingle Marco M. Z. Sharkawi
Noha H. Amin
Norhan R. Mohamed
Shimaa S. Zaki
Loah R. Hemeda
Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic study
Scientific Reports
Bortezomib
Melphalan
Prednisolone
LC-MS/MS method
Green chemistry
Pharmacokinetics
title Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic study
title_full Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic study
title_fullStr Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic study
title_full_unstemmed Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic study
title_short Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic study
title_sort novel environmental and sustainable approach for concurrent assay of antineoplastics in vmp regimen with a comprehensive pharmacokinetic study
topic Bortezomib
Melphalan
Prednisolone
LC-MS/MS method
Green chemistry
Pharmacokinetics
url https://doi.org/10.1038/s41598-025-15078-6
work_keys_str_mv AT marcomzsharkawi novelenvironmentalandsustainableapproachforconcurrentassayofantineoplasticsinvmpregimenwithacomprehensivepharmacokineticstudy
AT nohahamin novelenvironmentalandsustainableapproachforconcurrentassayofantineoplasticsinvmpregimenwithacomprehensivepharmacokineticstudy
AT norhanrmohamed novelenvironmentalandsustainableapproachforconcurrentassayofantineoplasticsinvmpregimenwithacomprehensivepharmacokineticstudy
AT shimaaszaki novelenvironmentalandsustainableapproachforconcurrentassayofantineoplasticsinvmpregimenwithacomprehensivepharmacokineticstudy
AT loahrhemeda novelenvironmentalandsustainableapproachforconcurrentassayofantineoplasticsinvmpregimenwithacomprehensivepharmacokineticstudy